SmithKline topical loperamide
Executive Summary
Licensing agreement signed with Adolor for worldwide (excluding Korea) prescription and OTC development and commercial rights to topical dermal loperamide product ADL 2-1294 for use in the treatment of inflammatory pain, itching and other undisclosed indications. Adolor will receive an up-front payment and up to $48 mil. from development milestone payments. ADL 2-1294 lacks the CNS side effects associated with other narcotic opioids because it does not cross the blood-brain barrier, Adolor says, making it the only opioid drug that is not in a DEA controlled-drug schedule
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth